Combined Advanced Targeted Therapy in Inflammatory Bowel Diseases: An Extensive Update

Nicole Cornet; Aiya Aboubakr; Waseem Ahmed; Robert Battat

doi:10.1093/ibd/izae189

Combined Advanced Targeted Therapy in Inflammatory Bowel Diseases: An Extensive Update

Inflamm Bowel Dis. 2024 Aug 29:izae189. doi: 10.1093/ibd/izae189. Online ahead of print.

Authors

Nicole Cornet¹, Aiya Aboubakr², Waseem Ahmed³, Robert Battat⁴

Affiliations

¹ Department of Medicine, NewYork Presbyterian-Weill Cornell Medicine, New York, NY, USA.
² Division of Gastroenterology, NewYork Presbyterian-Weill Cornell Medicine, New York, NY, USA.
³ Department of Gastroenterology, University of Colorado Crohn's and Colitis Center, Aurora, CO, USA.
⁴ Department of Gastroenterology and Hepatology, Center Hospitalier de l' Université de Montreal, Montreal, QC, Canada.

PMID: 39207309
DOI: 10.1093/ibd/izae189

No abstract available

Keywords: combined advanced targeted therapy; dual advanced therapy; inflammatory bowel disease.

Plain language summary

This article discusses the rationale for and the current data on the efficacy and safety of combined advanced targeted therapy (CATT) for the treatment of moderate-to-severe inflammatory bowel disease.